Provides full year 2009 revenue guidance of $95 million to $98
million HAYWARD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Solta
Medical, Inc. (NASDAQ:SLTM), a global leader in the medical
aesthetics market, today announced results for the third quarter
ended September 30, 2009. Revenue for the quarter was in-line with
the preliminary forecast provided on September 28th. Revenue for
the third quarter was $17.8 million, an increase of approximately
$4.7 million, or 36%, as compared to the third quarter 2008
reflecting increased revenue as a result of the acquisition of
Reliant Technologies, Inc. on December 23, 2008, and partially
offset by production and regulatory approval delays on new products
during the third quarter. "As we have previously disclosed, we
received 510K clearance for the Fraxel re:store DUAL system in
mid-October and resolved our production delays on the Thermage CPT
system at the end of the third quarter. We are fulfilling back
orders from customers and shipping both products," said Stephen J.
Fanning, Chairman of the Board, President and CEO of Solta Medical.
"Our illumiNATION tour continues to bring these latest
breakthroughs in Thermage and Fraxel systems directly to physicians
as it makes it way from city-to-city across the U.S. and Europe.
The tour has generated a very enthusiastic response to our new
products by physicians, prospective patients, and the media. As a
result, we are gaining momentum in the market place," added Mr.
Fanning. Solta Medical's reported results for the third quarter of
2009 include non-cash purchase price related charges, primarily
amortization of acquired intangible assets, of $1.2 million and
non-cash stock based compensation charges of $0.8 million. The GAAP
net loss for the quarter including these charges was $6.2 million,
or $0.13 per share as compared to a net loss of $1.1 million, or
$0.05 per share reported for the third quarter of 2008. The
non-GAAP net loss for the quarter excluding these charges was $4.2
million, or $0.09 per share as compared to non-GAAP net income of
$0.7 million, or $0.03 per share reported for the third quarter of
2008. Financial Goals for 2009 The Company updated its financial
goals for 2009 as follows: -- Revenue for the year in the range of
$95 million to $98 million -- Realize up to $25 million in cost
synergies as a result of the acquisition of Reliant Technologies,
Inc. This represents an increase of $6 million from the originally
stated goal in January 2009 of $19 million in cost synergies. --
Generate positive EBITDA for the full year 2009 -- Achieve a
non-GAAP gross margin in the range of 64% to 66% for the full year
2009 excluding non-cash amortization charges and non-cash purchase
price related charges. Non-GAAP Presentation To supplement the
condensed consolidated financial information presented on a GAAP
basis, management has provided non-GAAP gross margin, non-GAAP
operating income (loss), non-GAAP EBITDA, non-GAAP net income
(loss) and non-GAAP earnings (loss) per share measures that exclude
the impact of purchase price related charges, severance costs,
merger related costs, extraordinary loss on investments, and
stock-based compensation expenses, all net of income taxes. The
Company believes that these non-GAAP financial measures provide
investors with insight into what is used by management to conduct a
more meaningful and consistent comparison of the Company's ongoing
operating results and trends, compared with historical results.
This presentation is also consistent with management's internal use
of the measures, which it uses to measure the performance of
ongoing operating results, against prior periods and against our
internally developed targets. There are limitations in using these
non-GAAP financial measures because they are not prepared in
accordance with GAAP and may be different from non-GAAP financial
measures used by other companies. These non-GAAP financial measures
should not be considered in isolation or as a substitute for GAAP
financial measures. Investors and potential investors should
consider non-GAAP financial measures only in conjunction with the
Company's consolidated financial statements prepared in accordance
with GAAP and the reconciliation of non-GAAP financial measures
attached to this release. Conference Call Information Solta Medical
will host a conference call and webcast today, Tuesday, November 3,
2009, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the
financial results and current corporate developments. The dial-in
number for the conference call is 877-941-1465 for domestic
participants and 480-629-9678 for international participants. A
taped replay of the conference call will also be available
beginning approximately one hour after the call's conclusion and
will remain accessible for seven days. This replay can be accessed
by dialing 800-406-7325 for domestic callers and 303-590-3030 for
international callers. Both callers will need to use the Passcode
4171632#. To access the live webcast of the call, go to Solta
Medical's website at http://www.solta.com/ and click on Investor
Relations. An archived webcast will also be available at
http://www.solta.com/. About Solta Medical, Inc. Solta Medical,
Inc. is a global leader in the medical aesthetics market providing
innovative, safe, and effective anti-aging solutions for patients
which enhance and expand the practice of medical aesthetics for
physicians. The company offers products to address aging skin under
the industry's two premier brands: Thermage(R) and Fraxel(R).
Thermage is an innovative, non-invasive radiofrequency procedure
for tightening and contouring skin. As the leader in fractional
laser technology, Fraxel delivers minimally invasive clinical
solutions to resurface aging and sun damaged skin. Since 2002, over
one million Thermage and Fraxel procedures have been performed
worldwide. Thermage and Fraxel are the perfect complement for any
aesthetic practice. Our products are available in over 100
countries. For more information about Solta Medical, call
877-782-2286 or log on to http://www.solta.com/. Forward-Looking
Statements This press release contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995, including statements regarding our financial goals for
2009. Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks and
uncertainties, which may cause Solta Medical's actual results to
differ materially from the statements contained herein. Factors
that might cause such a difference include the possibility that the
market for the sale of these new products and initiatives does not
develop as expected, the remaining risks and uncertainties with the
integration process, and the risks relating to Solta Medical's
ability to achieve its stated financial goals as a result of, among
other things, economic conditions and consumer and physician
confidence causing changes in consumer and physician spending
habits that affect demand for our products and treatments. Further
information on potential risk factors that could affect Solta
Medical's business and its financial results are detailed in its
Form 10-K for the year ended December 31, 2008, its Form10-Q for
the quarter ended June 30, 2009, and other reports as filed from
time to time with the Securities and Exchange Commission. Undue
reliance should not be placed on forward-looking statements,
especially guidance on future financial performance, which speaks
only as of the date they are made. Solta Medical undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
they were made, or to reflect the occurrence of unanticipated
events. Solta Medical, Inc. CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS (in thousands of dollars, except share and per share
data) (unaudited) Three Months Ended Nine Months Ended September
30, September 30, 2009 2008 2009 2008 ---- ---- ---- ---- Net
revenue $17,753 $13,020 $70,415 $47,132 Cost of revenue 7,311 3,209
29,595 11,662 ----- ----- ------ ------ Gross margin 10,442 9,811
40,820 35,470 ------ ----- ------ ------ Operating expenses: Sales
and marketing 8,958 5,915 28,471 20,330 Research and development
4,239 2,150 12,104 7,054 General and administrative 3,793 2,575
11,563 10,173 ----- ----- ------ ------ Total operating expenses
16,990 10,640 52,138 37,557 ------ ------ ------ ------ Loss from
operations (6,548) (829) (11,318) (2,087) Interest and other income
195 635 432 1,781 Interest and other expense (136) - (287) - Gain
(loss) on investments 159 (863) 224 (863) --- ---- --- ---- Loss
before income taxes (6,330) (1,057) (10,949) (1,169) Provision
(benefit) for income taxes (84) 89 (13) 175 --- --- --- --- Net
loss $(6,246) $(1,146) $(10,936) $(1,344) ======= ======= ========
======= Net loss per share - basic $(0.13) $(0.05) $(0.23) $(0.06)
====== ====== ====== ====== Net loss per share - diluted $(0.13)
$(0.05) $(0.23) $(0.06) ====== ====== ====== ====== Weighted
average shares outstanding used in calculating net loss per share:
Basic 47,855,428 24,067,548 47,807,180 23,861,079 ==========
========== ========== ========== Diluted 47,855,428 24,067,548
47,807,180 23,861,079 ========== ========== ========== ==========
Solta Medical, Inc. NON-GAAP RECONCILIATION OF GROSS MARGIN,
OPERATING INCOME (LOSS), EBITDA, NET INCOME (LOSS) AND NET INCOME
(LOSS) PER SHARE (in thousands, except share and per share data)
(unaudited) Three Months Ended Nine Months Ended September 30,
September 30, 2009 2008 2009 2008 ---- ---- ---- ---- GAAP Gross
margin $10,442 $9,811 $40,820 $35,470 Non-GAAP adjustments to gross
margin: Purchase price related charges 895 - 4,919 - Stock-based
compensation 61 53 175 96 --- --- --- --- Non-GAAP gross margin
$11,398 $9,864 $45,914 $35,566 ======= ====== ======= =======
Non-GAAP gross margin as % of sales 64% 76% 65% 75% === === === ===
GAAP loss from operations $(6,548) $(829) $(11,318) $(2,087)
Non-GAAP adjustments to net loss from operations: Purchase price
related charges 1,229 - 5,904 - Severance expenses - - 118 -
Merger-related costs - 165 - 1,134 Stock-based compensation 823 887
2,476 2,789 --- --- ----- ----- Non-GAAP income (loss) from
operations $(4,496) $223 $(2,820) $1,836 Depreciation expenses 650
336 2,045 1,002 --- --- ----- ----- Non-GAAP EBITDA $(3,846) $559
$(775) $2,838 ======= ==== ===== ====== GAAP net loss $(6,246)
$(1,146) $(10,936) $(1,344) Non-GAAP adjustments to net loss:
Purchase price related charges 1,229 - 5,904 - Severance expenses -
- 118 - Merger-related costs - 131 - 1,075 Loss on investments -
863 - 863 Stock-based compensation 823 887 2,476 2,789 --- ---
----- ----- Non-GAAP net income (loss) $(4,194) $735 $(2,438)
$3,383 ======= ==== ======= ====== GAAP basic net loss per share
$(0.13) $(0.05) $(0.23) $(0.06) Non-GAAP adjustments to basic
income (loss) per share: Purchase price related charges 0.03 - 0.12
- Severance expenses - - - - Merger-related costs - $0.01 - 0.05
Loss on investments - $0.03 - 0.03 Stock-based compensation 0.02
$0.04 0.06 0.12 ---- ----- ---- ---- Non-GAAP basic net income
(loss) per share $(0.09) $0.03 $(0.05) $0.14 ====== ===== ======
===== Non-GAAP diluted net income (loss) per share $(0.09) $0.03
$(0.05) $0.14 ====== ===== ====== ===== GAAP weighted average
shares outstanding used in calculating basic net loss per share
47,855,428 24,067,548 47,807,180 23,861,079 ========== ==========
========== ========== GAAP weighted average shares outstanding used
in calculating diluted net loss per share 47,855,428 24,067,548
47,807,180 23,861,079 Adjustments for dilutive potential common
stock - 838,410 - 1,057,632 --- ------- --- --------- Weighted
average shares outstanding used in calculating non-GAAP diluted net
income (loss) per share 47,855,428 24,905,958 47,807,180 24,918,711
========== ========== ========== ========== Solta Medical, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars,
except share and per share data) (Unaudited) September 30, December
31, 2009 2008 ---- ---- ASSETS Current assets: Cash and cash
equivalents $14,723 $7,556 Marketable investments - 17,870 Accounts
receivable, net 9,100 5,119 Inventories, net 13,363 18,304 Prepaid
expenses and other current assets 3,198 4,074 ----- ----- Total
current assets 40,384 52,923 Property and equipment, net 6,036
6,841 Purchased intangible assets, net 37,849 40,999 Goodwill
47,289 48,158 Other assets 265 247 --- --- Total assets $131,823
$149,168 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities: Accounts payable $5,699 $8,080 Accrued liabilities
9,838 11,085 Accrued restructuring 307 3,549 Current portion of
deferred revenue 4,452 3,658 Short-term borrowings 7,411 12,399
Customer deposits 288 288 --- --- Total current liabilities 27,995
39,059 Deferred revenue, net of current portion 526 688 Term loan,
net of current portion 1,998 - Non-current tax liabilities 1,514
1,464 Other liabilities 306 133 --- --- Total liabilities 32,339
41,344 ------ ------ Stockholders' equity: Common stock, $0.001 par
value: 100,000,000 shares authorized 47,866,829 and 47,758,823
shares issued and outstanding at September 30, 2009 and December
31, 2008 48 48 Additional paid-in capital 168,274 165,680 Deferred
stock-based compensation - (2) Accumulated deficit (68,838)
(57,902) ------- ------- Total stockholders' equity 99,484 107,824
------ ------- Total liabilities and stockholders' equity $131,823
$149,168 ======== ======== DATASOURCE: Solta Medical, Inc. CONTACT:
Jack Glenn, Chief Financial Officer of Solta Medical, Inc.,
+1-510-786-6890; or investors, Doug Sherk of EVC Group,
+1-415-896-6820, , for Solta Medical, Inc. Web Site:
http://www.solta.com/
Copyright